Abstract
The hypoxia-inducible factor HIF-1 has been shown to be mandatory for the cellular adaptation to hypoxia. In addition, evidence has been provided that HIF-1 can mediate various stress responses and that it may play an important role under inflammatory conditions even independently of hypoxia. HIF-1 is a heterodimer consisting of an α-subunit which is subject to tight regulation, and a β-subunit, also termed ARNT, which appears to be constitutively expressed. In addition to the complex network controlling the cellular content of HIF-1α at the level of protein stability, recent evidence showed that HIF-1α levels can also be regulated at the mRNA level. In fact, transcriptional regulatory networks seem to be an additional way of controlling HIF-1α levels and may open new therapeutic options to modulate HIF-1α also under non-hypoxic conditions.
Keywords: HIF, nuclear factor kappa b, transcription, promoter, reactive oxygen species, hypoxia
Current Pharmaceutical Design
Title: Regulation of HIF-1α at the Transcriptional Level
Volume: 15 Issue: 33
Author(s): Agnes Gorlach
Affiliation:
Keywords: HIF, nuclear factor kappa b, transcription, promoter, reactive oxygen species, hypoxia
Abstract: The hypoxia-inducible factor HIF-1 has been shown to be mandatory for the cellular adaptation to hypoxia. In addition, evidence has been provided that HIF-1 can mediate various stress responses and that it may play an important role under inflammatory conditions even independently of hypoxia. HIF-1 is a heterodimer consisting of an α-subunit which is subject to tight regulation, and a β-subunit, also termed ARNT, which appears to be constitutively expressed. In addition to the complex network controlling the cellular content of HIF-1α at the level of protein stability, recent evidence showed that HIF-1α levels can also be regulated at the mRNA level. In fact, transcriptional regulatory networks seem to be an additional way of controlling HIF-1α levels and may open new therapeutic options to modulate HIF-1α also under non-hypoxic conditions.
Export Options
About this article
Cite this article as:
Gorlach Agnes, Regulation of HIF-1α at the Transcriptional Level, Current Pharmaceutical Design 2009; 15 (33) . https://dx.doi.org/10.2174/138161209789649420
DOI https://dx.doi.org/10.2174/138161209789649420 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Vascular Compartments of Neovascularization: Spotlight on the Microcirculation
Current Pharmaceutical Biotechnology Conceptual Issues in Psychiatric Neuroimaging: An Update
Current Topics in Medicinal Chemistry Anabolic Androgenic Steroids and Intracellular Calcium Signaling: A Mini Review on Mechanisms and Physiological Implications
Mini-Reviews in Medicinal Chemistry Recent Advances in Hematopoietic Stem Cell-Mediated Regeneration
Recent Patents on Regenerative Medicine Anti-HER2 Cancer Therapy and Cardiotoxicity
Current Pharmaceutical Design Role of Endothelial Nitric Oxide in Cerebrovascular Regulation
Current Pharmaceutical Biotechnology Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Clinical Science of Calcium Channel Blocker to Inhibit Hypertensive Vascular Injury
Current Hypertension Reviews Low Estimated Glomerular Filtration Rate is Associated with High Recurrence Rate and Poor Prognosis of Hemorrhage Stroke
Current Neurovascular Research Improving Protein Stability and Controlling Protein Release by Adding Poly (Cyclohexane -1, 4 -Diyl Acetone Dimethylene Ketal) to PLGA Microspheres
Current Drug Delivery Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design Novel Treatments in Diabetic Nephropathy
Current Hypertension Reviews Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Inflammation and Coagulation in Urticaria and Angioedema
Current Vascular Pharmacology Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology Retracted: Tocotrienols and its Role in Cardiovascular Health- a Lead for Drug Design
Current Pharmaceutical Design Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design <i>In Vivo</i> Tracking of Novel SPIO-Molday ION Rhodamine-B™-Labeled Human Bone Marrow-Derived Mesenchymal Stem Cells After Lentivirus- Mediated COX-2 Silencing: A Preliminary Study
Current Gene Therapy Cilostazol: A New Drug in the Treatment Intermittent Claudication
Recent Patents on Cardiovascular Drug Discovery